Artios Pharma

Artios Pharma

Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

August 2018

Artios Pharma raises a $84,000,000 series B round from Andera Partners, AbbVie Biotech Ventures, M Ventures, Pfizer Ventures, Novartis Venture Fund, SV Health Investors, IP Group and Arix Bioscience plc.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.